-+ 0.00%
-+ 0.00%
-+ 0.00%

On November 19, according to Xingqiao Capital, Suzhou Ruiyi Xulian Medical Technology Co., Ltd. completed the Pre-A+ round of financing of nearly 100 million yuan. This round of financing was jointly led by PricewaterhouseCapital and Reconstruction Investment, followed by Songhe Capital and BeiGong Investment, with Xingqiao Capital acting as the sole financial advisor for subsequent financing. The funds raised in this round will mainly be used to promote the core product, the cerebrospinal interface, into clinical trials; support the completion of mass production of the modular implantable bidirectional brain-computer interface platform for brain reading and writing; and at the same time, rely on this platform to expand new indications such as language decoding, visual reconstruction, and depression into clinical research.

Zhitongcaijing·11/19/2026 01:25:05
Listen to the news
On November 19, according to Xingqiao Capital, Suzhou Ruiyi Xulian Medical Technology Co., Ltd. completed the Pre-A+ round of financing of nearly 100 million yuan. This round of financing was jointly led by PricewaterhouseCapital and Reconstruction Investment, followed by Songhe Capital and BeiGong Investment, with Xingqiao Capital acting as the sole financial advisor for subsequent financing. The funds raised in this round will mainly be used to promote the core product, the cerebrospinal interface, into clinical trials; support the completion of mass production of the modular implantable bidirectional brain-computer interface platform for brain reading and writing; and at the same time, rely on this platform to expand new indications such as language decoding, visual reconstruction, and depression into clinical research.